We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
CB<sub>1</sub> blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans.
- Authors
Bergholm, R; Sevastianova, K; Santos, A; Kotronen, A; Urjansson, M; Hakkarainen, A; Lundbom, J; Tiikkainen, M; Rissanen, A; Lundbom, N; Yki-Järvinen, H
- Abstract
Objective:Studies in mice have suggested that endocannabinoid blockade using the cannabinoid receptor type 1 (CB1) blocker rimonabant prevents obesity-induced hepatic steatosis.Design and subjects:To determine effects of rimonabant on liver fat in humans, we measured liver fat content by proton magnetic resonance spectroscopy in 37 subjects who used either a CB1 blocker rimonabant or placebo in a double-blind, randomized manner. This was retrospectively compared with a historical hypocaloric diet weight loss group (n=23).Results:Weight loss averaged 8.5±1.4 kg in the rimonabant, 1.7±1.0 kg in the placebo and 7.5±0.2 kg in the hypocaloric diet group (P<0.001, rimonabant vs placebo; NS, rimonabant vs hypocaloric diet). Liver fat decreased more in the rimonabant (5.9% (2.5-14.6%) vs 1.8% (0.9-3.5%), before vs after) than in the placebo group (6.8% (2.2-15.7%) vs 4.9% (1.6-7.8%), before vs after, P<0.05). The percentage change in body weight correlated closely with the percentage loss of liver fat (r=0.70, P>0.0001). The decreases in liver fat were comparable between the rimonabant and the young historical hypocaloric diet groups.Conclusions:We conclude that, unlike in mice, in humans rimonabant decreases liver fat in proportion to weight loss.
- Subjects
FATTY liver; LOW-calorie diet; WEIGHT loss; CANNABINOID receptors; RIMONABANT; PLACEBOS; PROTON magnetic resonance spectroscopy
- Publication
International Journal of Obesity, 2013, Vol 37, Issue 5, p699
- ISSN
0307-0565
- Publication type
Article
- DOI
10.1038/ijo.2012.116